Jobevne (bevacizumab-nwgd) vs Zirabev (bevacizumab-bvzr)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline
Jobevne (bevacizumab-nwgd)
Marketed by Biocon and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Zirabev (bevacizumab-bvzr)
Marketed by Pfizer
NCT02364999 · Phase 3 · completed
This was a randomized, double-blind, active-controlled trial with 719 participants, using tumor response by RECIST as its primary clinical endpoint. PF-06439535 had a confirmed response rate of 45.3% versus 44.6% with European bevacizumab, and the prespecified equivalence margins were met, supporting a strong evidence grade.
Reported efficacy
Objective Response Rate (ORR) by Week 19 (25 weeks): Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89) (met)
Result source: NCT02364999
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Jobevne (bevacizumab-nwgd) | Zirabev (bevacizumab-bvzr) |
|---|---|---|
| PFS, median | —Not reported | —Not reported |
| OS, median | —Not reported | —Not reported |
| ORR | —Not reported | 45.3% vs 44.6%vs Bevacizumab-EUNCT02364999 |
| Duration of response, median | —Not reported | 8.4 vs 6.6vs Bevacizumab-EUNCT02364999 |
PFS, median
- Jobevne (bevacizumab-nwgd)
- —Not reported
- Zirabev (bevacizumab-bvzr)
- —Not reported
OS, median
- Jobevne (bevacizumab-nwgd)
- —Not reported
- Zirabev (bevacizumab-bvzr)
- —Not reported
ORR
- Jobevne (bevacizumab-nwgd)
- —Not reported
- Zirabev (bevacizumab-bvzr)
- 45.3% vs 44.6%vs Bevacizumab-EUNCT02364999
Duration of response, median
- Jobevne (bevacizumab-nwgd)
- —Not reported
- Zirabev (bevacizumab-bvzr)
- 8.4 vs 6.6vs Bevacizumab-EUNCT02364999
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Jobevne (bevacizumab-nwgd): no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Jobevne (bevacizumab-nwgd): 0 of 4 rows · Zirabev (bevacizumab-bvzr): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Zirabev (bevacizumab-bvzr) |
|---|---|
| Dropout rate | 46.1% NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 |
| Discontinued due to AEs | — NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 |
| Serious AEs | 22.8% NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 |
| Most frequent reported AEs | alopecia 46.6% anaemia 28.7% fatigue 20.5% NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Zirabev (bevacizumab-bvzr)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Jobevne (bevacizumab-nwgd)'s landscape · Zirabev (bevacizumab-bvzr)'s landscape